Phase 2 N=43 Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Lichen Planopilaris · Frontal Fibrosing Alopecia
Primary: Change in Patient-Reported Itch — -0.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=98 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Response Rate in MEDI4736-treated Participants — 16 percentage of participants
Phase 2 N=40 Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Recurrent Adult Hepatocellular Carcinoma
Primary: Median Progression Free Survival (PFS) — 10.32 months
N/A N=30 Argus® II Retinal Stimulation System Feasibility Protocol
Retinitis Pigmentosa
Primary: Visual Acuity — 2 Participants
Phase 4 N=20 Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
End Stage Renal Disease
Primary: Number of Participants With Treatment-related Adverse Events and Treatment Failure — 2; 2; 1; 1 Participants
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
Phase 2 N=18 Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
Dry Eye Disease
Primary: Mean Change in Goblet Cell Area — -38.8; -6.7 um
Phase 1 N=1 Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
HIV Infections · Systemic Lupus Erythematosus
Primary: Change in Response Rates of nAb Responses to the Vaccine Strains and a Global Panel of Heterologous Env-pseudotyped Viruses
N/A N=72 MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South
Hiv · Adolescent Behavior · Family Relations
Primary: Acceptance of an HIV Test at Study Completion — 8; 8; 9; 10 Participants
Phase 2 N=195 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events — 3; 3; 3; 3 Participants
Phase 2 N=183 A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
Osteoarthritis, Knee
Primary: Change From Baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale (WOMAC-A) Score in Patients Receiving a Single Dose…
Phase 3 N=427 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular…
N/A N=18 Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
Pancreatic Cancer
Primary: Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity — 0 Participants
Phase 2 N=78 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536